OPHTHOTECH CORPORATION (NASDAQ:OPHT) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December31, 2017, the Company will announce during the 36thAnnual J.P. Morgan Healthcare Conference, which began on January8, 2018, that it expects to report that it had approximately $167,000,000 in cash, cash equivalents and marketable securities as of December31, 2017.
The information contained in this Item 2.02 of Form 8-K is unaudited and preliminary, and does not present all information necessary for an understanding of the Company’s financial condition as of December31, 2017 and its results of operations for the three months and year ended December31, 2017. The audit of the Company’s financial statements for the year ended December31, 2017 is ongoing and could result in changes to the information set forth above. The Company anticipates making a public announcement of its results of operations for the fourth quarter and fiscal year ended December31, 2017 on or about February28, 2018.
Item 2.02 Regulation FD Disclosure.
The Company’s President and Chief Executive Officer, Glenn Sblendorio, will be presenting on January11, 2018 at the 36thAnnual J.P. Morgan Healthcare Conference. The slides to be used during Mr.Sblendorio’s presentation are attached hereto as Exhibit 99.1 and the information contained therein is incorporated herein by reference.
The information in this Form8-K (including Item 2.02, Item 2.02 and Exhibit99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.
Item 2.02 Financial Statements and Exhibits.
The following Exhibit relating to Item 2.02 and Item 2.02 shall be deemed to be furnished, and not filed:
Ophthotech Corp. ExhibitEX-99.1 2 ophtjpmorganhealthcareco.htm EXHIBIT 99.1 ophtjpmorganhealthcareco 1
NASDAQ: OPHT January 2018
36th Annual J.P. Morgan Healthcare Conference
Glenn Sblendorio,…To view the full exhibit click here
About OPHTHOTECH CORPORATION (NASDAQ:OPHT)
Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV). Fovista is being tested in Phase III clinical development. In addition, it has initiated additional clinical trials to evaluate the potential additional benefits of Fovista administered in combination with anti-VEGF drugs in wet AMD patients, known as Fovista Expansion Studies. Zimura has completed a small, multicenter, uncontrolled, open label Phase I/IIa clinical trial.
